New drug eliminates aggressive cancers

A new cancer drug, 2141-V11, has shown remarkable results in a Phase I clinical trial, with two patients achieving complete remission. The drug, a modified CD40 agonist antibody, was injected directly into tumors, leading to systemic immune responses that eliminated cancer throughout the body without severe side effects. This approach, developed by Rockefeller University's Jeffrey V. Ravetch, is now being tested in further trials for various aggressive cancers, aiming to understand and improve patient response rates.